CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company specializing in treatments for age-related neurologic disorders, has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The event will take place in New York on May 20, 2025.
Company management will engage in a fireside chat scheduled from 5:00 to 5:30 PM ET and will also conduct one-on-one investor meetings. The fireside chat will be available via webcast through the company's website and a dedicated event platform.
CervoMed Inc. (NASDAQ: CRVO), un'azienda in fase clinica specializzata in trattamenti per disturbi neurologici legati all'età, ha annunciato la sua partecipazione alla 3ª Conferenza Annuale BioConnect per Investitori di H.C. Wainwright. L'evento si terrà a New York il 20 maggio 2025.
Il management dell'azienda parteciperà a una conversazione informale programmata dalle 17:00 alle 17:30 ET e terrà anche incontri individuali con gli investitori. La conversazione informale sarà trasmessa in webcast tramite il sito web dell'azienda e una piattaforma dedicata all'evento.
CervoMed Inc. (NASDAQ: CRVO), una empresa en etapa clínica especializada en tratamientos para trastornos neurológicos relacionados con la edad, ha anunciado su participación en la 3ª Conferencia Anual BioConnect para Inversores de H.C. Wainwright. El evento se llevará a cabo en Nueva York el 20 de mayo de 2025.
La dirección de la empresa participará en una charla informal programada de 5:00 a 5:30 PM ET y también realizará reuniones individuales con inversores. La charla informal estará disponible vía webcast a través del sitio web de la empresa y una plataforma dedicada al evento.
CervoMed Inc. (NASDAQ: CRVO)는 연령 관련 신경 질환 치료에 전문화된 임상 단계 회사로, H.C. Wainwright 제3회 연례 BioConnect 투자자 회의에 참여한다고 발표했습니다. 행사는 2025년 5월 20일 뉴욕에서 개최됩니다.
회사 경영진은 동부 표준시 기준 오후 5시부터 5시 30분까지 예정된 비공식 대화에 참여하며, 1:1 투자자 미팅도 진행할 예정입니다. 비공식 대화는 회사 웹사이트와 전용 이벤트 플랫폼을 통해 웹캐스트로 제공됩니다.
CervoMed Inc. (NASDAQ : CRVO), une société en phase clinique spécialisée dans les traitements des troubles neurologiques liés à l'âge, a annoncé sa participation à la 3e conférence annuelle BioConnect pour investisseurs de H.C. Wainwright. L'événement se tiendra à New York le 20 mai 2025.
La direction de l'entreprise participera à une discussion informelle prévue de 17h00 à 17h30 (heure de l'Est) et tiendra également des réunions individuelles avec les investisseurs. La discussion informelle sera diffusée en webcast via le site web de la société et une plateforme dédiée à l'événement.
CervoMed Inc. (NASDAQ: CRVO), ein klinisch tätiges Unternehmen, das sich auf Behandlungen altersbedingter neurologischer Erkrankungen spezialisiert hat, hat seine Teilnahme an der 3. jährlichen BioConnect Investorenkonferenz von H.C. Wainwright angekündigt. Die Veranstaltung findet am 20. Mai 2025 in New York statt.
Die Unternehmensleitung wird an einem Gespräch am Kamin von 17:00 bis 17:30 Uhr ET teilnehmen und zudem Einzelgespräche mit Investoren führen. Das Gespräch am Kamin wird über die Webseite des Unternehmens und eine spezielle Eventplattform per Webcast verfügbar sein.
- None.
- None.
BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held in New York, NY, on Tuesday, May 20, 2025.
Presentation Details
Format: Fireside Chat
Date: Tuesday, May 20, 2025
Time: 5:00 – 5:30 PM ET
Webcast Link: https://journey.ct.events/view/ff005743-cd3c-4c4c-bd4d-ba8d0c84c859
The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.
About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause clinical disease expression in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579
FAQ
When is CervoMed (CRVO) presenting at the H.C. Wainwright BioConnect Conference 2025?
What type of company is CervoMed (CRVO)?
How can investors access CervoMed's (CRVO) presentation at the H.C. Wainwright conference?
What activities will CervoMed (CRVO) participate in at the H.C. Wainwright conference?
